Oral News and Research

RSS

Phase II open-label study demonstrates that high-risk populations adhere well to daily regimen of PrEP

Results from HPTN 067, a Phase II, randomized, open-label study, demonstrate most study participants had higher coverage of sex events and better adherence when they were assigned to the daily dosing arm, investigators from the HIV Prevention Trials Network (HPTN) reported today at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver, Canada.

21 Jul 2015

Researchers successfully treat eczema patients using rheumatoid arthritis drug

Researchers at Yale School of Medicine have successfully treated patients with moderate to severe eczema using a rheumatoid arthritis drug recently shown to reverse two other disfiguring skin conditions, vitiligo and alopecia areata. The study is evidence of a potential new era in eczema treatment, they report.

21 Jul 2015

Resveratrol and quercetin may improve efficacy of existing chemotherapeutic cancer drug

Resveratrol and quercetin, two polyphenols that have been widely studied for their health properties, may soon become the basis of an important new advance in cancer treatment, primarily by improving the efficacy and potential use of an existing chemotherapeutic cancer drug.

17 Jul 2015

Alternative approach to treat fatal blood clots found to be more effective in patients

Potentially fatal blood clots account for thousands of emergency room visits each year and often those patients are admitted to the hospital, treated with an injectable anticoagulant and monitored for a few days.

17 Jul 2015

Einstein-Montefiore researchers to present multiple findings at Alzheimer's Association International Conference

Investigators at Montefiore Health System and Albert Einstein College of Medicine of Yeshiva University will present multiple findings at the Alzheimer's Association International Conference, taking place July 18-23 in Washington, D.C. Research topics include risk factors for developing amnestic mild cognitive impairment (aMCI)—a condition characterized by memory problems, and is most often a precursor of Alzheimer's dementia.

16 Jul 2015

Protagonist Therapeutics closes $40 million Series C financing

Protagonist Therapeutics, Inc., a company developing novel, orally stable peptide therapeutics for gastrointestinal diseases and disorders, today announced the closing of a $40 million Series C financing.

16 Jul 2015

Oral PAH treatments stave off clinical decline

Oral treatments for pulmonary arterial hypertension reduce patients’ risk of clinical worsening but have little effect on survival, say the authors of a meta-analysis.

15 Jul 2015

Futura Medical develops new generation of topical pain relief

Futura Medical has developed a "new generation" of topical pain relief with two products that target more active ingredients directly to the point of pain. The new products have the potential to transform the pain relief market, according to chief executive James Barder.

15 Jul 2015

Survey: Over 30% of parents say their children missed school due to oral health problem

This past school year was a painful one for many U.S. students, according to a new survey out today from Delta Dental. The survey finds that more than 30 percent of parents said their children between the ages of six and 12 had to miss school due to an oral health problem.

15 Jul 2015

Ferrer begins Lorediplon phase IIa trial in patients with insomnia disorder

Ferrer, a privately-held Spanish pharmaceutical company, today announces the first patient has been recruited into a phase IIa clinical trial to test the efficacy, safety and tolerability profile of Lorediplon in adult patients with insomnia disorder. The study is scheduled to be completed by Q4, 2016.

14 Jul 2015

Accuray announces presentation of CyberKnife System data at AAPM annual meeting

Accuray Incorporated announced today that studies on the clinical use of the CyberKnife System, the only robotic SBRT system capable of tracking and automatically correcting for target motion, continue to demonstrate the benefits of its precise, innovative treatment delivery techniques.

14 Jul 2015

Clinical data on TomoTherapy System presented at AAPM 2015

Accuray Incorporated announced today that studies on the clinical use of the TomoTherapy System continue to demonstrate its mainstream use and the benefits of its gold-standard treatment planning and delivery capabilities. More than 30 studies were presented during poster or oral sessions at the 57th Annual Meeting of the American Association of Physicists in Medicine held in Anaheim, California July 12 – July 16, 2015.

14 Jul 2015

ANI acquires 22 previously marketed generic drug products for $25 million from Teva Pharmaceuticals

ANI Pharmaceuticals, Inc. today announced that it has acquired 22 previously marketed generic drug products from Teva Pharmaceuticals for $25 million in cash and a percentage of future gross profits from product sales. The acquisition includes 19 solid-oral dosage products, and 3 oral suspension products.

13 Jul 2015

Lixiana (edoxaban) recommended for treating, preventing recurrent DVT and PE in adults

The National Institute for Health and Care Excellence has recommended a new treatment to help patients suffering from blood clots in the legs and lungs.

13 Jul 2015

Researchers discover role of RORC mutations in patients with candidiasis and mycobacteriosis

The discovery of bi-allelic mutations in RORC in patients with candidiasis and mycobacteriosis revealed the pivotal role of RORC in mucocutaneous immunity to Candida and in systemic immunity to Mycobacterium in humans.

13 Jul 2015

Trial results show routine oral cholera vaccination programme protects people living in endemic regions

An oral cholera vaccine given as part of routine health services is safe and protects against severe cholera in children and adults in urban Bangladesh where the disease is endemic, according to the first real-life trial of this vaccine published in The Lancet.

10 Jul 2015

Elsevier, NCI implement two-way linking between research articles on ScienceDirect and datasets in caNanoLab

Elsevier, a world-leading provider of scientific, technical and medical information products and services, and the US National Cancer Institute, a world-leading institute for cancer research, today announced that they have implemented two-way linking between research articles on ScienceDirect and datasets stored in NCI's cancer Nanotechnology Laboratory (caNanoLab) data portal.

9 Jul 2015

Galmed signs License Agreement for development of blood-based companion diagnostic tool

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases, announced today that it has entered into a Research, Option and License Agreement ("License Agreement") and a Share Purchase Agreement with One Way Liver Genomics S.L., for the development of a non-invasive, blood-based companion diagnostic tool.

8 Jul 2015

Out-of-pocket expenses for oral contraceptive pills, IUD decrease since the ACA took effect: Study

Average out-of-pocket spending for oral contraceptive pills and the intrauterine device (IUD), the two most common forms of contraception for women, has decreased significantly since the Affordable Care Act (ACA) took effect.

8 Jul 2015

Southern Research receives $22 million to support HIV cure initiative

Southern Research has been awarded a seven-year contract of up to $22 million to support research that could contribute to the cure of HIV disease. Under this contract, Southern Research will develop and standardize assays that quantitate latent reservoirs of HIV.

7 Jul 2015

Oral News and Research

Phase II open-label study demonstrates that high-risk populations adhere well to daily regimen of PrEP

Researchers successfully treat eczema patients using rheumatoid arthritis drug

Resveratrol and quercetin may improve efficacy of existing chemotherapeutic cancer drug

Alternative approach to treat fatal blood clots found to be more effective in patients

Einstein-Montefiore researchers to present multiple findings at Alzheimer's Association International Conference

Protagonist Therapeutics closes $40 million Series C financing

Oral PAH treatments stave off clinical decline

Futura Medical develops new generation of topical pain relief

Survey: Over 30% of parents say their children missed school due to oral health problem

Ferrer begins Lorediplon phase IIa trial in patients with insomnia disorder

Accuray announces presentation of CyberKnife System data at AAPM annual meeting

Clinical data on TomoTherapy System presented at AAPM 2015

ANI acquires 22 previously marketed generic drug products for $25 million from Teva Pharmaceuticals

Lixiana (edoxaban) recommended for treating, preventing recurrent DVT and PE in adults

Researchers discover role of RORC mutations in patients with candidiasis and mycobacteriosis

Trial results show routine oral cholera vaccination programme protects people living in endemic regions

Elsevier, NCI implement two-way linking between research articles on ScienceDirect and datasets in caNanoLab

Galmed signs License Agreement for development of blood-based companion diagnostic tool

Out-of-pocket expenses for oral contraceptive pills, IUD decrease since the ACA took effect: Study

Southern Research receives $22 million to support HIV cure initiative

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News